Advances in CXCR7 Modulators
CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels.
Top-30
Journals
|
1
2
3
|
|
|
Cancers
3 publications, 7.89%
|
|
|
Molecular Pharmacology
2 publications, 5.26%
|
|
|
Journal of Medicinal Chemistry
2 publications, 5.26%
|
|
|
Blood
2 publications, 5.26%
|
|
|
PeerJ
1 publication, 2.63%
|
|
|
Molecular Medicine Reports
1 publication, 2.63%
|
|
|
Journal of Bio-X Research
1 publication, 2.63%
|
|
|
Cells
1 publication, 2.63%
|
|
|
Clinical and Experimental Nephrology
1 publication, 2.63%
|
|
|
Cellular and Molecular Life Sciences
1 publication, 2.63%
|
|
|
Pharmacology and Therapeutics
1 publication, 2.63%
|
|
|
Seminars in Cancer Biology
1 publication, 2.63%
|
|
|
Pharmacological Research
1 publication, 2.63%
|
|
|
Cellular Signalling
1 publication, 2.63%
|
|
|
Drug Discovery Today
1 publication, 2.63%
|
|
|
FASEB Journal
1 publication, 2.63%
|
|
|
Cancer Medicine
1 publication, 2.63%
|
|
|
MedComm
1 publication, 2.63%
|
|
|
Russian Journal of Developmental Biology
1 publication, 2.63%
|
|
|
Molecular Biology Reports
1 publication, 2.63%
|
|
|
Advances in Clinical Medicine
1 publication, 2.63%
|
|
|
ACS Medicinal Chemistry Letters
1 publication, 2.63%
|
|
|
Renal Failure
1 publication, 2.63%
|
|
|
Critical Reviews in Oncology/Hematology
1 publication, 2.63%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.63%
|
|
|
Organic Process Research and Development
1 publication, 2.63%
|
|
|
Cell Biochemistry and Biophysics
1 publication, 2.63%
|
|
|
International Immunopharmacology
1 publication, 2.63%
|
|
|
Expert Opinion on Therapeutic Patents
1 publication, 2.63%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
Elsevier
8 publications, 21.05%
|
|
|
MDPI
5 publications, 13.16%
|
|
|
Springer Nature
5 publications, 13.16%
|
|
|
American Chemical Society (ACS)
4 publications, 10.53%
|
|
|
Wiley
3 publications, 7.89%
|
|
|
American Society of Hematology
2 publications, 5.26%
|
|
|
Taylor & Francis
2 publications, 5.26%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
1 publication, 2.63%
|
|
|
PeerJ
1 publication, 2.63%
|
|
|
Spandidos Publications
1 publication, 2.63%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.63%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 2.63%
|
|
|
Pleiades Publishing
1 publication, 2.63%
|
|
|
Hans Publishers
1 publication, 2.63%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 2.63%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 2.63%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.